DOCSLIB.ORG

Downloads/ Outbreak Starts

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Downloads/ Outbreak Starts feature PATENTS Ebola as a case study for the patent landscape of medical countermeasures for emerging infectious diseases A survey of patenting activity can facilitate coordination of R&D activities to fght emerging infectious diseases. ethods to combat Ebola virus a 200 196 2,000 disease (EVD) have gradually 175 improved since its discovery in Cumulative patent family number M 1–3 1976 (refs. ). EVD has caused over 33,000 150 infections and 14,000 deaths worldwide, 1,500 with most cases occurring in Africa. Ebola virus (EBOV)—named for the Ebola River, 114113 located near Yambuku, Democratic Republic 100 1,000 of the Congo (formerly Zaire)—is the cause 74 76 75 Patent families 73 4 of the disease . The discovery of the Reston 59 62 54 56 545557 Ebola virus in the Philippines in 1989 50 46 45 showed that EBOV is also present in Asia. 39 500 During the first outbreak, in 1976, 25 14 131614 9 9 9 12 improper nursing techniques such as 1 1 2 1 1 1 3 1 2 2 2 4 3 3 3 3 4 1 0 0 reuse of syringes for different patients and 6 4 7 9 1 3 5 7 8 9 1 2 3 5 7 9 1 3 5 7 9 0 3 4 5 7 9 7 2 4 6 0 4 6 8 0 2 4 6 8 11 2 6 8 0 close contact with infected blood were 195 196197 197197 198198 198198 198198198198 198199 199199 199 199199199 199199 199200 200200 200200 200200 200200 200201 20 201 201201 201201 201201 201202 the main source of human-to-human Year of first application transmission5. A better understanding of methods of virus transmission during b 133 133 the 1994 Cote d’Ivoire outbreak led to the Families with no granted applications use of personal protective equipment and Families with at least one granted application 104 single-use syringes, which helped in the 100 96 control of transmission. The international public health community helped contain 63 the disease by staffing local hospitals 60 51 53 and providing necessary equipment and Patent families 50 49 5 42 42 37 education for health care workers . 34 31 31 32 29 33 33 29 28 26 The 2014 outbreak of EVD caused more 23 23 25 24 23 20 21 17 17 18 18 16 14 than 28,000 cases and 11,000 deaths—more 11 77 7 8 8 8 9 9 6 54 45 6 5 5 than all previous EVD outbreaks combined . 1 1 2 1 1 1 21 1 2 2 2 22 3 21 21 3 31 3 3 2 1 0 Several factors contributed to the devastating 6 7 4 7 9 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 11 2 3 4 5 6 7 8 9 0 195 196 197 197 197 198 198 198 198 198 198 198 198 198 199 199 199 199 199 199 199 199 199 199 200 200 200 200 200 200 200 200 200 200 201 20 201 201 201 201 201 201 201 201 202 effects of this outbreak, such as the delay between identification of cases and reporting Year of first application to the World Health Organization (WHO), Fig. 1 | Analysis of patent application and granting frequencies. a, Number of patent families against the spread of the disease to urban areas, application years as a bar chart and cumulative chart. There were two peaks in the number of patent and the weak response of the international applications that coincide with two EVD outbreaks. b, Families that had at least one granted patent community7. The outbreak also highlighted were counted in the granted families group. The rest of the patent families were counted in no granted lack of proper medical countermeasures families group. The gap between granted and not granted patent applications widened with increase in (MCMs) in diagnosis of, vaccination against the number of patent applications. and treatment of the disease8. WHO has since included EVD on the list of priority pathogens with the potential of severe outbreaks for which to control an EVD outbreak forced WHO be more specific. However, the application few or no MCMs exist9 and has drafted an to call for “rapid, sensitive, safe and simple of rapid diagnostic tests in combination R&D roadmap to accelerate collaborative EBOV diagnostic tests” as a crucial MCM with PCR-based methods was suggested development of MCMs against the disease8. in November 2014 (ref. 10). Following to be more effective11. Lack of data from The vital importance of rapid isolation this call, several tests, including various randomized controlled trials made it of infected patients based on the clinical rapid diagnostic tests, became available4. difficult to draw conclusions about the diagnosis that could be further confirmed PCR-based methods, which detected one or efficacy of therapeutics against EVD. To with the results of a readily available test two of the EBOV genes were considered to address this difficulty, WHO developed an NATURE BIOTECHNOLOGY | VOL 39 | JULY 2021 | 799–808 | www.nature.com/naturebiotechnology 799 feature a WO 609 US 482 AU 155 CN 142 EP 99 JP 37 RU 22 KR 12 UK 9 CA 4 TW 2 Jurisdiction DE 2 ZA 1 PH 1 NZ 1 FR 1 EA 1 CZ 1 AT 1 0 200 400 600 Publications b WO 1 1 1 1 3 6 1 8 16 36 16 39 22 18 32 23 21 19 14 17 20 73 63 53 64 41 US 2 3 1 2 3 2 4 10 18 25 23 24 19 14 24 23 29 17 16 21 20 64 59 30 16 13 AU 1 1 1 2 1 1 2 2 5 3 2 8 2 6 3 6 5 3 6 7 7 7 3 5 6 1 4 4 9 3 10 10 10 8 1 CN 1 1 2 1 3 1 3 4 3 24 30 29 15 18 7 EP 1 1 2 2 1 1 1 1 1 2 1 1 1 4 1 5 3 5 5 9 2 5 5 1 10 5 8 4 5 4 1 1 JP 2 2 1 3 4 3 1 2 3 2 3 1 2 1 1 1 1 2 1 1 RU 1 2 1 1 6 3 4 3 1 KR 2 1 3 3 2 1 UK 1 1 2 2 1 1 1 CA 1 1 2 TW 1 1 1 1 Jurisdiction DE ZA 1 PH 1 NZ 1 FR 1 EA 1 CZ 1 AT 1 19561967 19741977 1979 1981 1982 1983 1984 1985 1986 1987 1988 1989 1990 1991 19921993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 20042005 2006 20072008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 20192020 Year Fig. 2 | Analysis of jurisdictions. a, Offices of the first patent application are grouped and counted. The number of families that were filed through the PCT is more than in other types of applications. b, Patent applications for each patent office plotted versus time in years. Applications in most patent offices are concentrated in the years after 2000. However, applications in some patent offices, such as AU, EP and JP, are more evenly distributed. WO, world (PCT); US, United States; AU, Australia; CN, China; EP, European Patent Office; JP, Japan; RU, Russia; KR, South Korea; UK, United Kingdom; CA, Canada; TW, Taiwan; DE, Germany; ZA, South Africa; PH, the Philippines; NZ, New Zealand; FR, France; EA, Eurasian Patent Organization; CZ, Czech Republic; AT, Austria. ethical framework to bridge compassionate which led to the approval of REGN-EB3, and European Medicines Agency (EMA) for access to investigational therapeutics and or Inmazeb (atoltivimab, maftivimab and the prevention of EVD14 and is being used clinical trials12. Following the development odesivimab), as the first drug to treat EVD13. in the Democratic Republic of the Congo of this guidance, a clinical trial was initiated For vaccine development, GP1,2 according to a ring vaccination strategy. in the Democratic Republic of the Congo protein was considered the major EBOV The EMA has also granted marketing to test the monoclonal antibodies ZMapp, immunogen. A recombinant vesicular authorization for a vaccine composed of mAb114 and REGN-EB3, as well as the stomatitis virus (VSV) pseudotyped a two-dose regimen of Zabdeno (Ad26. viral polymerase inhibitor remdesivir. In with Ebola Zaire glycoprotein, ZEBOV) and Mvabea (MVA-BN-Filo). this trial, patients who received REGN-EB3 rVSVΔG-ZEBOV-GP, was approved by the One of the lessons of the 2014 EVD or mAb114 showed higher survival rates, US Food and Drug Administration (FDA) outbreak was that collaborative development 800 NATURE BIOTECHNOLOGY | VOL 39 | JULY 2021 | 799–808 | www.nature.com/naturebiotechnology feature a 1. Univ California 27 b 1 3 2 3 2 2 1 1 1 3 2 4 1 1 2 c 1 3 15 10 2. Harvard College 23 2 1 1 1 1 1 1 1 2 1 3 7 3 2 5 1 3 14 3. Univ Emory 21 3 2 1 1 2 2 3 1 4 1 2 1 1 3 1 3 6 11 4. Massachusetts Inst Technology 20 4 1 2 1 1 1 2 1 10 1 4 4 1 15 5. US Gov Health & Human Serv 17 5 1 4 6 2 2 1 1 5 1 2 1 12 1 6.
Load more

Recommended publications
  • Refreshing the Biologic Pipeline 2020
    news feature Credit: Science Lab / Alamy Stock Photo Refreshing the biologic pipeline 2020 In the absence of face-to-face meetings, FDA and industry implemented regulatory workarounds to maintain drug and biologics approvals. These could be here to stay. John Hodgson OVID-19 might have been expected since 1996) — a small miracle in itself “COVID-19 confronted us with the need to severely impair drug approvals (Fig. 1 and Table 1). to better triage sponsors’ questions,” says Cin 2020. In the event, however, To the usual crop of rare disease and Peter Marks, the director of the Center for industry and regulators delivered a small genetic-niche cancer treatments, 2020 Biologics Evaluation and Research (CBER) miracle. They found workarounds and also added a chimeric antigen receptor at the FDA. “That was perhaps the single surrogate methods of engagement. Starting (CAR)-T cell therapy with a cleaner biggest takeaway from the pandemic related in January 2020, when the outbreak veered manufacturing process and the first to product applications.” Marks says that it westward, the number of face-to face approved blockbuster indication for a became very apparent with some COVID- meetings declined rapidly; by March, small-interfering RNA (siRNA) — the 19-related files that resolving a single they were replaced by Webex and Teams. European Medicines Agency’s (EMA) issue can help a sponsor enormously and (Secure Zoom meeting are to be added registration of the RNA interference accelerate the development cycle. Before this year.) And remarkably, by 31 December, (RNAi) therapy Leqvio (inclisiran) for COVID-19, it was conceivable that a small the US Food and Drug Administration cardiovascular disease.
    [Show full text]
  • Atoltivimab, Maftivimab, and Odesivimab
    PATIENT & CAREGIVER EDUCATION Atoltivimab, Maftivimab, and Odesivimab This information from Lexicomp® explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider. What is this drug used for? It is used to treat infections caused by Ebolavirus. What do I need to tell my doctor BEFORE I take this drug? If you are allergic to this drug; any part of this drug; or any other drugs, foods, or substances. Tell your doctor about the allergy and what signs you had. If you are breast-feeding. Do not breast-feed while you take this drug. This drug may interact with other drugs or health problems. Tell your doctor and pharmacist about all of your drugs (prescription or OTC, natural products, vitamins) and health problems. You must check to make sure that it is safe for you to take this drug with all of your drugs and health problems. Do not start, stop, or change the dose of any drug without checking with your doctor. Atoltivimab, Maftivimab, and Odesivimab 1/5 What are some things I need to know or do while I take this drug? Tell all of your health care providers that you take this drug. This includes your doctors, nurses, pharmacists, and dentists. Talk with your doctor before getting any vaccines. Use of some vaccines with this drug may either raise the chance of an infection or make the vaccine not work as well. Tell your doctor if you are pregnant or plan on getting pregnant.
    [Show full text]
  • October 2020
    PharmNOTES Summary about new FDA-approved products, new indications, first-time generics, and WHAT IS IN THE PIPELINE. From: OCTOBER 2020 Date: 11/06/2020 ©2020 PharmPix. All rights reserved Table of Contents Page News 3 New FDA Approved Products 4-5 Inmazeb™ (atoltivimab, maftivimab, and odesivimab-ebgn) 4 Veklury™ (remdesivir) 5 New FDA Approved Formulations, Dosage Forms, Combination Products and Other Differences 6 New FDA Approved Indications 7 New First-Time Generic Drug Approval 8 Pipeline 9 References 10 2 NEWS ……………………………………………………………………………………………………………... Drug issue Date Details Avoid Use of NSAIDs in 10/15/2020 The FDA issued a warning to avoid the use of Non-steroidal Anti-inflammatory Drugs (NSAIDs) during pregnancy at 20 weeks or Pregnancy at 20 Weeks later. The use of NSAIDs around 20 weeks or later in pregnancy may cause serious kidney problems in the fetus, low levels of or Later amniotic fluids, and other complications. Previously NSAIDs labels warned to avoid use during the last three (3) months of pregnancy due to the risk of premature closure of the fetal ductus arteriosus. The FDA now requires changes in the prescribing information for both prescription and over the counter (OTC) NSAIDs. Recommendations for healthcare professionals: • Advise pregnant women to avoid the use of NSAIDs at 20 weeks of pregnancy or later. • If NSAIDs are necessary during 20 to 30 weeks of pregnancy, limit treatment to the lowest dose possible and for the shortest duration. Consider ultrasound monitoring of amniotic fluid if treatment extends over 48 hours. If low levels of amniotic fluid are identified, discontinue the NSAID.
    [Show full text]
  • A Short Overview of Ebola Virus Disease
    Short Communication Journal of Volume 6:4, 2021 DOI: 10.37421/jidm.2021.6.173 Infectious Diseases and Medicine A Short Overview of Ebola Virus Disease Akshay Thiwari* Department of Virology, University of Hyderabad, Hyderabad, Telangana, India Ebola [1] is an uncommon but lethal virus that causes fever, body Treatment for Ebola aches, diarrhea, and, in some cases, internal and external bleeding. The Ebola has no known cure, though researchers are working on one. For immune system and organs are harmed as the virus spreads through the the treatment of Ebola [2], two drug therapies have been authorized. Inmazeb body. As a result, the number of blood-clotting cells decreases. As a is a compound that consists of three monoclonal antibodies (atoltivimab, consequence, there is a lot of uncontrollable bleeding. Ebola hemorrhagic maftivimab, and odesivimab-ebgn). Ebanga (ansuvimab-zykl) is a monoclonal fever was the previous name for the outbreak, but it is now known as Ebola antibody that is given as an injection. It aids in stopping the virus from reaching virus. It kills up to 90% of those who become infected. the cell receptor. Doctors treat Ebola symptoms [3] with the following How does one contract Ebola? medication. Ebola isn't as infectious as viruses like the common cold, influenza, or Electrolytes and fluids, Oxygen (O2), Medication for high blood pressure, measles. Contact with the skin or bodily fluids of an infected animal, such as Transfusions of blood, and other diseases'. a monkey, chimp, or fruit bat, transmits the disease to humans. Then it Facts on Ebola passes from one person to the next in the same manner.
    [Show full text]
  • Antibodies to Watch in 2021 Hélène Kaplona and Janice M
    MABS 2021, VOL. 13, NO. 1, e1860476 (34 pages) https://doi.org/10.1080/19420862.2020.1860476 PERSPECTIVE Antibodies to watch in 2021 Hélène Kaplona and Janice M. Reichert b aInstitut De Recherches Internationales Servier, Translational Medicine Department, Suresnes, France; bThe Antibody Society, Inc., Framingham, MA, USA ABSTRACT ARTICLE HISTORY In this 12th annual installment of the Antibodies to Watch article series, we discuss key events in antibody Received 1 December 2020 therapeutics development that occurred in 2020 and forecast events that might occur in 2021. The Accepted 1 December 2020 coronavirus disease 2019 (COVID-19) pandemic posed an array of challenges and opportunities to the KEYWORDS healthcare system in 2020, and it will continue to do so in 2021. Remarkably, by late November 2020, two Antibody therapeutics; anti-SARS-CoV antibody products, bamlanivimab and the casirivimab and imdevimab cocktail, were cancer; COVID-19; Food and authorized for emergency use by the US Food and Drug Administration (FDA) and the repurposed Drug Administration; antibodies levilimab and itolizumab had been registered for emergency use as treatments for COVID-19 European Medicines Agency; in Russia and India, respectively. Despite the pandemic, 10 antibody therapeutics had been granted the immune-mediated disorders; first approval in the US or EU in 2020, as of November, and 2 more (tanezumab and margetuximab) may Sars-CoV-2 be granted approvals in December 2020.* In addition, prolgolimab and olokizumab had been granted first approvals in Russia and cetuximab saratolacan sodium was first approved in Japan. The number of approvals in 2021 may set a record, as marketing applications for 16 investigational antibody therapeutics are already undergoing regulatory review by either the FDA or the European Medicines Agency.
    [Show full text]
  • CDER Therapeutic Biologic Products List
    CDER Therapeutic Biologic Products This list is intended to include all the Center for Drug Evaluation and Research (CDER) user fee billable therapeutic biological products and potencies approved under Section 351 of the Public Health Service Act. The Orange Book includes a section entitled "Drug Products with Approval under Section 505 of the Act Administered by CBER." Included on that list are several products that have been transferred to CDER which would be considered billable also. Program fees are assessed for each potency in which the approved (non-revoked, non-suspended) product is manufactured in final dosage form. When evaluating the specific strength or potency of a drug in final dosage form for purposes of assessing program fees for liquid parenteral biological products, CDER intends to take into consideration both the total amount of drug substance in mass or units of activity in a product and the concentration of drug substance (mass or units of activity per unit volume of product). Biologic products considered to have a different strength or potency in a final dosage form will be given separate entries in the Biologics List and assessed separate program fees. An auto-injector that has the same strength or potency as a prefilled syringe or vial will generally be assessed a separate prescription drug program fee. In certain circumstances, products which have been discontinued from marketing but are still licensed are not assessed program fees. Those products are identified on the CDER Discontinued Biologic Product List section. The potency information contained in this list is based on information in our database.
    [Show full text]
  • Risk Assessment and Risk Mitigation Review(S)
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 761169Orig1s000 RISK ASSESSMENT and RISK MITIGATION REVIEW(S) Division of Risk Management (DRM) Office of Medication Error Prevention and Risk Management (OMEPRM) Office of Surveillance and Epidemiology (OSE) Center for Drug Evaluation and Research (CDER) Application Type BLA Application Number 761169 PDUFA Goal Date October 25, 2020 OSE RCM # 2020-264 Reviewer Name(s) Elizabeth Everhart, MSN, RN, ACNP Team Leader Naomi Boston, PharmD Acting Deputy Division Doris Auth, PharmD Director Review Completion Date August 10, 2020; date entered into DARRTS, August 20, 2020 Subject Evaluation of Need for a REMS Established Name atoltivimab – odesivimab – maftivimab (REGN-EB3) Trade Name Inmazeb Name of Applicant Regeneron Pharmaceuticals, Inc. Therapeutic Class Human IgG monoclonal antibody Formulation Solution for infusion Dosing Regimen 50 mg of each mAb/kg (3mL/kg) IV (b) (4) × 1 1 Reference ID: 4659652 Table of Contents EXECUTIVE SUMMARY ............................................................................................................................................................3 1 Introduction........................................................................................................................................................................3 2 Background .........................................................................................................................................................................3 2.1 Product Information..............................................................................................................................................3
    [Show full text]
  • 761169Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 761169Orig1s000 OTHER REVIEW(S) LABEL AND LABELING REVIEW Division of Medication Error Prevention and Analysis (DMEPA) Office of Medication Error Prevention and Risk Management (OMEPRM) Office of Surveillance and Epidemiology (OSE) Center for Drug Evaluation and Research (CDER) *** This document contains proprietary information that cannot be released to the public*** Date of This Review: October 7, 2020 Requesting Office or Division: Division of Antivirals (DAV) Application Type and Number: BLA 761169 Product Name, Dosage Form, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) and Strength: Injection 241.7 mg/241.7 mg/241.7 mg per 14.5 mL (16.67 mg/16.67 mg/16.67 mg per mL) Product Type: Multi-Ingredient Product Rx or OTC: Prescription (Rx) Applicant/Sponsor Name: Regeneron Pharmaceuticals, Inc. (Regeneron) FDA Received Date: February 25, 2020 OSE RCM #: 2020-263 DMEPA Safety Evaluator: Valerie S. Vaughan, PharmD DMEPA Associate Director of Mishale Mistry, PharmD, MPH Nomenclature and Labeling: 1 1 REASON FOR REVIEW As part of the approval process for Inmazeb injection, 241.7 mg/241.7 mg/241.7 mg per 14.5 mL (16.67 mg/16.67 mg/16.67 mg per mL), the Division of Antivirals (DAV) requested that we review the proposed labels and labeling for areas that may lead to medication errors. 2 MATERIALS REVIEWED We considered the materials listed in Table 1 for this review. The Appendices provide the methods and results for each material reviewed. Table 1. Materials Considered for this
    [Show full text]
  • Pipeline Report November 2020
    Pipeline Report November 2020 Pipeline Report November 2020 © 2020 AcariaHealth. All rights reserved. Page 1 This quarterly at-a-glance publication is developed by our Clinical Pharmacy Drug Information team to increase your understanding of the drug pipeline, Table of Contents ensuring you’re equipped with insights to prepare for shifts in pharmacy benefit management. In this issue, you’ll learn more about key themes and notable drugs: Recent Drug Approvals 1 > On COVID-19, the FDA granted full approval to Veklury (remdesivir) for the treatment of COVID-19. Veklury is approved for use in hospitalized adults and pediatric patients (≥ 12 years of age and weighing ≥ 40 Upcoming Products 6 kg), and represents the very first therapy to garner full FDA approval for COVID-19. Other therapies will follow, gaining market access through EUA (LLY’s Bamlanivimab and Olumiant, and <likely> Regeneron’s Biosimilars 14 REGN-COV2). With the US crossing the 11 million total coronavirus infection mark, demand for these agents will be high while supply of the antibody treatment will be especially tight. The vaccine race accelerates as there are now two m-RNA based candidates both showing greater than 94% Generic Specialty Agents 15 efficacy in study populations. Both vaccines require 2 doses. Neither has FDA approval, and EUA reviews are pending. Supplies will be limited for months to come. Pfizer has stated it could produce 50 million doses by the end of 2020, and Moderna has promised up to 20 million doses in the same time frame. During 2021 Pfizer forecasts 1.3 billion doses while Moderna states between 500 million and 1 billion.
    [Show full text]
  • COVID-19) Pandemic—Principles Underlying Prevention
    Infection Control & Hospital Epidemiology (2021), 42, 457–460 doi:10.1017/ice.2020.1427 Commentary Lessons learned in infection prevention for Ebola virus disease and the coronavirus disease 2019 (COVID-19) pandemic—Principles underlying prevention Erica S. Shenoy MD, PhD1,2,3 and David J. Weber MD, MPH4,5 1Infection Control Unit, Massachusetts General Hospital, Boston, Massachusetts, 2Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, 3Harvard Medical School, Boston, Massachusetts, 4Division of Infectious Disease, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina and 5Department of Hospital Epidemiology, UNC Medical Center, Chapel Hill, North Carolina Delivery of care to patients with highly communicable diseases balances the potential risk of transmission from the patient-to- healthcare personnel (HCP) with the risks to the patient of delayed or reduced access to needed interventions. The risk of transmission to HCP depends on many factors described by the chain of trans- mission (Fig. 1), including the establishment of a reservoir (human, animal, inanimate environment), exit of the infectious agent from the reservoir and survival in the environment, with transmission by direct or indirect contact, droplet, airborne modes or combina- tions of these modes, and finally entry of the infectious agent via a portal of entry to a susceptible host at an inoculum sufficient to establish infection. Efforts to prevent transmission in healthcare settings—among patients, visitors, and HCP—are all aimed at interrupting the chain of transmission. These efforts include, in addition to correct and consistent use of personal protective equip- ment (PPE) plus rapid institution of appropriate isolation precau- tions as indicated by the mode of transmission, multiple other interventions that minimize the risk of nosocomial transmission.
    [Show full text]
  • NETTER, Jr., Robert, C. Et Al.; Dann, Dorf- (21) International Application
    ll ( (51) International Patent Classification: (74) Agent: NETTER, Jr., Robert, C. et al.; Dann, Dorf- C07K 16/28 (2006.01) man, Herrell and Skillman, 1601 Market Street, Suite 2400, Philadelphia, PA 19103-2307 (US). (21) International Application Number: PCT/US2020/030354 (81) Designated States (unless otherwise indicated, for every kind of national protection av ailable) . AE, AG, AL, AM, (22) International Filing Date: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, 29 April 2020 (29.04.2020) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (25) Filing Language: English DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, (26) Publication Language: English KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (30) Priority Data: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 62/840,465 30 April 2019 (30.04.2019) US OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, (71) Applicants: INSTITUTE FOR CANCER RESEARCH TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW. D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER [US/US]; 333 Cottman Av¬ (84) Designated States (unless otherwise indicated, for every enue, Philadelphia, PA 191 11-2497 (US). UNIVERSTIY kind of regional protection available) . ARIPO (BW, GH, OF KANSAS [US/US]; 245 Strong Hall, 1450 Jayhawk GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, Boulevard, Lawrence, KS 66045 (US).
    [Show full text]
  • International Nonproprietary Names for Pharmaceutical Substances (INN)
    WHO Drug Information, Vol. 32, No. 4, 2018 Proposed INN: List 120 International Nonproprietary Names for Pharmaceutical Substances (INN) Notice is hereby given that, in accordance with article 3 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances, the names given in the list on the following pages are under consideration by the World Health Organization as Proposed International Nonproprietary Names. The inclusion of a name in the lists of Proposed International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy. Lists of Proposed (1–117) and Recommended (1–78) International Nonproprietary Names can be found in Cumulative List No. 17, 2017 (available in CD-ROM only). The statements indicating action and use are based largely on information supplied by the manufacturer. This information is merely meant to provide an indication of the potential use of new substances at the time they are accorded Proposed International Nonproprietary Names. WHO is not in a position either to uphold these statements or to comment on the efficacy of the action claimed. Because of their provisional nature, these descriptors will neither be revised nor included in the Cumulative Lists of INNs. Dénominations communes internationales des Substances pharmaceutiques (DCI) Il est notifié que, conformément aux dispositions de l'article 3 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques les dénominations ci-dessous sont mises à l'étude par l'Organisation mondiale de la Santé en tant que dénominations communes internationales proposées.
    [Show full text]